Studies on the urinary assay of CYP-mediated endogenous corticosteroid metabolites with a LC-MS method
Studies on the urinary assay of CYP-mediated endogenous corticosteroid metabolites with a LC-MS method
批准号:
18590542
负责人:
ECHIZEN Hirotoshi
金额:
$2.79万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2009
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Interindividual variability of the drug metabolizing enzyme activity is associated with those of drug responses and adverse drug reactions. Recent advances in molecular biology have made it possible to account for a part of interindividual variability of important drug metabolizing enzymes, particularly cytochrome P-450s (CYPs) in the light of pharmacogenomics. Nevertheless, it has also become evident that a large interindividual variability still exists in subjects or patients having none of the previously known loss-of-function SNPs in the respective CYP isoforms. Thus, there is a surge of interest to reappraise for assessing CYP isoform activity as phenotype individually. We have previously reported that in vivo CYP3A4 activity may be assessed by urinary excretion of 6β-hydroxycortisol, a CYP3A4 metabolite of adrenal cortisol, or its metabolic ratio of cortisol. In order to extend this idea to other steroid hormones which are thought to be metabolized by different CYP isoforms, we aimed to establish a comprehensive assay method using HPLC-UV and LC-MS. We have established a simultaneous assay method for urinary 2- and 4-hydroxyestradiol and 17-hydroxyprogesterone, of which metabolism are associated with CYP1A2 and CYP2C19, respectively, with an HPLC-UV method as a preliminary study. We found that there is a large interindividual variability in the urinary excretion of those sex steroid metabolites, indicating that there is a good chance to measure interindividual variability of the these CYP activities. Then, we advanced our study to establish a LC-MS method. We consider that this method would be useful for a population study where a large number of clinical samples are to be assayed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2007
期刊:
Invest Ophthalmol Vis Sci 48
影响因子:
--
作者:
[Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T.]
通讯作者:
Iwata T.
Proteomic & Transcriptomic Analyses of Retinal Pigment Epithelial Cells Exposed to REF-1/TFPI-2, a Growth Promoting Factor
暴露于生长促进因子 REF-1/TFPI-2 的视网膜色素上皮细胞的蛋白质组学和转录组学分析
DOI:
--
发表时间:
2007
期刊:
Invest Ophthalmol Vis Sci 48
影响因子:
--
作者:
[Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T.]
通讯作者:
Iwata T.
白癬患者に対するイトラコナゾールパルス療法施行時のCYP3A活性の経時的変化
癣患者伊曲康唑冲击治疗期间 CYP3A 活性的时程变化
DOI:
--
发表时间:
2009
期刊:
影响因子:
--
作者:
[柴田壮一, 高橋晴美, 小野紀子, 和田直子, 久保博昭, 篠崎公一, 齋藤京, 稲本伸子, 越前宏俊, 厚田幸一郎]
通讯作者:
厚田幸一郎
Bioequivalence studies between 0.5, 1, and 5 mg warfarin potassium tablets of new formula and those of standard formula
新配方0.5、1、5 mg华法林钾片与标准配方的生物等效性研究
DOI:
--
发表时间:
2008
期刊:
Jpn Pharmacol Ther 36
影响因子:
--
作者:
[Dochiguchi Y, Shiba S, Masuda Y, Kurihara Y, Hasegawa S, Echizen H]
通讯作者:
Echizen H
DOI:
--
发表时间:
2007
期刊:
Invest Ophthalmol Vis Sci 48
影响因子:
--
作者:
[Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T.]
通讯作者:
Iwata T.
共 21 条
Inhibition of CYP3A activity by a standard triple drug regimen including clarithromycin for eradication of Helicobacter pylori infection
-
批准号:14572166
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:2002
-
负责人:ECHIZEN Hirotoshi
-
依托单位:
CYP3A ISOFORMS MEDIATED ENANTIOSELECTIVE DRUG METABOLISM WITH HUMAN LIVER MICROSOMES
-
批准号:06672286
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.09万
-
财政年份:1994
-
负责人:ECHIZEN Hirotoshi
-
依托单位:
海外基金